Posts

Momentum at the Frontier: Prostate Cancer Advances of March 2026

Image
Informed Prostate Cancer Support Group (IPCSG)  ·  Member Newsletter March 2026 Volume 2026, Issue 3 San Diego, California Research & Clinical Trials Edition March 2026 has delivered one of the most clinically consequential months in prostate cancer research in recent memory. From landmark overall survival results presented at the ASCO Genitourinary Cancers Symposium to first-in-human alpha emitter data, a $12 million research investment, and new FDA clearances for local therapy, the field has advanced simultaneously on multiple fronts — radiopharmaceuticals, precision genomics, epigenetic therapy, and focal ablation. This edition summarizes every major development our community needs to know about, with full citations and trial identifiers to aid your conversations with your oncologist.  At a Glance Summary of Key March 2026 Developments ...
Post a Comment
Read more

The Estrogen Patch: A Proven Alternative to ADT Injections

Image
Estradiol Patch Matches LHRH Agonists for Locally Advanced Prostate Cancer | MedPage Today IPCSG Newsletter Informed Prostate Cancer Support Group March 2026 Treatment Updates Treatment & Research Spotlight Bottom Line Up Front (BLUF) A large, 15-year British clinical trial—just published in the New England Journal of Medicine on March 25, 2026—shows that estradiol skin patches work just as well as the standard hormone-blocking injections for controlling locally advanced prostate cancer. The patches matched LHRH agonist shots for preventing metastasis and preserving life, while cutting hot flashes in half. The main tradeoff is a higher rate of breast tissue swelling (gynecomastia). For men who struggle with hot flashes, fatigue, or bone loss from conventional ADT, this evidence-backed alternative is now firmly on the table—and it costs a fraction of standard injections. Hormone Therapy Research A landmark New Engla...
Post a Comment
Read more

When Is Hormone Therapy Really Worth It?

Image
For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit - The ASCO Post New landmark research redraws the map on androgen deprivation therapy — who truly benefits, how long treatment should last, and what the very real side effects mean for your quality of life. IPCSG Medical Education Staff  |  Sources: The Lancet, JAMA Oncology, ASCO GU 2026, NCI, ASCO, UCLA Health, University Hospitals Seidman Cancer Center, European Urology Oncology, Scientific Reports Bottom Line Up Front (BLUF) Androgen deprivation therapy (ADT) — hormone therapy that lowers testosterone — has long been a cornerstone of prostate cancer treatment, but three major new analyses published in early 2026 have clarified when it actually saves lives and when it may do more harm than good. For men receiving salvage radiation after prostatectomy, ADT appears to offer a meaningful survival benefit only if their pr...
Post a Comment
Read more